

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)



EP 1 591 527 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:

02.11.2005 Bulletin 2005/44

(51) Int Cl.7: C12N 15/13, C07K 16/46,

C12P 21/08, C12N 5/10,

A61K 39/395

(21) Application number: 04704324.5

(86) International application number:
PCT/JP2004/000549

(22) Date of filing: 22.01.2004

(87) International publication number:
WO 2004/072286 (26.08.2004 Gazette 2004/35)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated Extension States:

AL LT LV MK

(30) Priority: 23.01.2003 JP 2003014793

(71) Applicants:

- ONO PHARMACEUTICAL CO., LTD.
Osaka-shi, Osaka 541-8526 (JP)
- Honjo, Tasuku
Kyoto-shi, Kyoto 606-0001 (JP)

(72) Inventors:

- HONJO, Tasuku
Kyoto-shi, Kyoto 606-0001 (JP)

• SHIBAYAMA, Shiro,

Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)

• TAKEDA, Kazuhiko,

Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)

• MATSUO, Masayoshi,

Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)

• YOSHIDA, Takao,

Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)

• MIYAMOTO, Masakazu,

Minase Research Inst. Ono Pharm.
Mishima-gun, Osaka 618-8585 (JP)

(74) Representative: Henkel, Feiler & Hänel

Möhlstrasse 37

81675 München (DE)

(54) **SUBSTANCE SPECIFIC TO HUMAN PD-1**

(57) The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a mem-

brane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

EP 1 591 527 A1

Description**Field of the Invention**

5 [0001] The present invention relates to antibodies specific to human PD-1, bispecific antibodies comprising antibodies against human T cell receptor complex or human B cell receptor complex, polynucleotides encoding them, and the usage of the bispecific antibodies.

Background of the Invention

10 [0002] The immune system acquired the mechanism that can respond to various foreign antigens. The mechanism takes the diversity of an antigen receptor by recombination of V, (D) and J fragment in T cells and B cells. Although this mechanism brought about a result that produces autoreactive lymphocytes, these autoreactive lymphocytes are removed by the negative selection in thymus or bone marrow, and are further controlled by the self-tolerance mechanism of clonal deletion or anergy in periphery.

15 [0003] Although it is thought that an autoimmune disease is developed by the breakdown of self-tolerance, the researches using various disease murine model have been conducted to elucidate the mechanism of pathogenesis. However, the etiology of an autoimmune disease and the molecular mechanism of self-tolerance remain unclear. In such a situation, existence of the mouse which shows the symptoms of an autoimmune disease caused by a single gene deficient is very important for study the etiology of an autoimmune disease from a molecular biological viewpoint. CTLA4-/mouse which causes lethal systemic lymphocytes infiltration (Waterhouse P., et al., *Science*, 270:985-988, 1995; Tivol E.A., et al., *Immunity*, 3:541-547, 1995), SHP-1 deficient mothaten mice (Shultz L.D., et al., *Cell*, 73: 1445-1454, 1993), lyn-/mouse which shows the symptoms of glomerular nephritis (Hibbs M.L., et al., *Cell*, 83:301-311, 1995), and FCRIIB-/-mouse (Bolland S. & Ravetch J.V., *Immunity*, 13:277-285, 2000) are the representation, and the relations of these molecules and self-tolerance has been studied.

20 [0004] The PD-1 gene, which belongs to the immunoglobulin super family, encodes a 55 kDa type I transmembrane protein. Both mouse PD-1 and human PD-1 consist of 288 amino acids, and have signal peptide at N terminal (20 amino acid) and hydrophobic region in the middle part, which is a transmembrane region (*The EMBO J.*, 11(11): 3887-3895, 1992); Japanese patent Publication No. 5-336973; EMBUGenBank/DDJB Acc. No. X67914, *Genomics*, 23:704, 1994; Japanese patent Publication No. 7-291996 (U.S. Patent No. 5629204).

25 [0005] In thymus, PD-1 is expressed at the transition phase between CD4-/CD8-to CD4+/CD8+ stage on thymocytes (Nishimura H., et al., *Int. Immunol.*, 8:773-780 (1996), Nishimura H., et al., *J. Exp. Med.*, 191:891-898 (2000)). In periphery, PD-1 is expressed on T cells and B cells activated through the antigen receptor (Agata Y., et al., *Int. Immunol.*, 8:765-772 (1996)), and on activated myeloid lineage cells such as macrophages.

30 [0006] PD-1 has ITIM (Immunoreceptor tyrosine-based inhibitory motif) in its intracellular region. Therefore, PD-1 is a negative regulator in immune responses. Since PD-1 deficient mice developed a lupus-like glomerular nephritis and arthritis (C57BL/6 genetic background) (Nishimura H., et al., *Int. Immunol.*, 10:1563-1572, 1998, Nishimura H., et al., *Immunity*, 11:141-151, 1999) and dilated cardiomyopathy-like disease (BALB/c genetic background) (Nishimura H., et al., *Science*, 291:319-322 (2001)), it became clear that PD-1 serves as a regulator for the development of autoimmune disease, especially for the maintenance of self tolerance. Further it has been reported that graft rejection is regulated by inhibition of PD-1 signal (*Journal of Immunology*, 169, 11:6543-6553 (2001)).

Disclosure of the Invention

35 [0007] It is thought that PD-1 is a regulator of various autoimmune diseases, and that it is one of causative genes of autoimmune diseases. Control of the PD-1 function can bring about the medical treatment and diagnosis of suppression or enhancement of the immune function, infection, transplant rejection, and neoplasm etc. As a result of keen examination, the present inventors reached the present invention concerning the substances that controls the function of PD-1.

40 [0008] Stimuli on lymphocytes which control immunity are transmitted mainly through T cell receptor (TCR) in case of T cells, and B cell receptor (BCR) in case of B cells, and then intracellular phosphorylation plays an important role in the molecular mechanism.

45 [0009] Since it has been elucidated that PD-1 negatively regulates various immunocompetent cells such as lymphocytes and myeloid cells etc. and PD-1 has ITIM (Immunoreceptor tyrosine-based inhibitory motif) in its intracellular region, the present inventors considered that the recruit of de-phosphorylation enzymes (phosphatases) could be involved in the molecular mechanism in the inhibitory signal transduction mediated by PD-1. Therefore, it was hypothesized that making PD-1 colocalize with TCR or BCR can display the PD-1 function.

50 [0010] The present inventors confirmed that the inhibitory signal of PD-1 was transmitted with the substance which

physically cross-links PD-1 to TCR or BCR. First, the present inventors confirmed that the above idea was right using anti-PD-1 antibodies and anti-CD3 antibodies. CD3 is a membrane protein expressed on T cells and is one component of TCR complexes. The divalent antibodies were constructed by bridging anti-PD-1 antibodies and anti-CD3 antibodies. The present invention was completed by isolating each cDNA encoding anti-human PD-1 antibody and anti-human TCR antibody and producing bispecific antibody produced by constructing expression vectors that can express fusions proteins comprising each antigen-recognition site of both antibodies.

[0011] The present invention relates to the followings:

- (1) A substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells, and a linker.
- (2) The substance specific to human PD-1 according to (1), wherein the part that recognizes human PD-1 is an antibody against human PD-1 or a partial fragment thereof.
- (3) The substance specific to human PD-1 according to (1), wherein the part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells is an antibody against the membrane protein or a partial fragment thereof.
- (4) The substance specific to human PD-1 according to (1), comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against the membrane protein on cell membrane of human PD-1-expressing cells or a partial fragment thereof, and a linker.
- (5) The substance specific to human PD-1 according to any one of (1), (3) and (4), wherein the membrane protein is human T cell receptor complex or human B cell receptor complex.
- (6) The substance specific to human PD-1 according to (1) or (4), wherein the linker is a peptide.
- (7) A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human T cell receptor complex or a partial fragment thereof, and a linker.
- (8) A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human B cell receptor complex or a partial fragment thereof, and a linker.
- (9) The bispecific antibody according to (7) or (8), wherein the linker is a peptide.
- (10) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
- (11) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:4, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
- (12) A polypeptide complex comprising the polypeptides according to (10) and (11).
- (13) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added.
- (14) A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, which is the bispecific antibody according to any one of (7) to (9).
- (15) A polynucleotide encoding the polypeptide according to any one of (10), (11), (13) and (14), a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
- (16) A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:9, a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
- (17) A duplication or expression vector comprising the polynucleotide according to (15) or (16).
- (18) A host cell transformed by the duplication or expression vector according to (17).
- (19) A manufacturing method of the substance according to any one of (1) to (6), comprising culturing the host cell according to (18) under conditions to express the substance.
- (20) A manufacturing method of the bispecific antibody according to any one of (7) to (9), comprising culturing the host cell according to (18) under conditions to express the bispecific antibody.
- (21) A manufacturing method of the polypeptide according to any one of (10) to (14), comprising culturing the host cell according to (18) under conditions to express the polypeptide.
- (22) A therapeutic and/or preventive pharmaceutical composition for human PD-1 related-diseases, comprising an effective amount of the substance according to any one of (1) to (6), the bispecific antibody according to any one of (7) to (9), the polypeptide complex according to (12), or the polypeptide according to (13) or (14).

(23) The therapeutic and/or preventive pharmaceutical composition according to (22), wherein the human PD-1 related-diseases are diseases selected from neurodegenerative disease, autoimmune disease, collagenosis, organ transplantation rejection, tumour, and infectious disease.

(24) The therapeutic and/or preventive pharmaceutical composition according to (22), wherein the neurodegenerative diseases are diseases selected from geropsychosis, Alzheimer disease, Down syndrome, Parkinson's disease, Creutzfeldt-jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt-Jakob disease.

(25) The therapeutic and/or preventive pharmaceutical composition according to (22), wherein the autoimmune diseases are diseases selected from glomerular nephritis, arthritis, dilated cardiomyopathy-like disease, ulcerous colitis, Sjogren syndrome, Crohn disease, systemic erythematoses, chronic rheumatoid arthritis, multiple sclerosis, psoriasis, allergic contact dermatitis, polymyositis, pachyderma, periarteritis nodosa, rheumatic fever, vitiligo vulgaris, insulin dependent diabetes mellitus, Behcet disease, Hashimoto disease, Addison disease, dermatomyositis, myasthenia gravis, Reiter syndrome, Graves' disease, anaemia perniciosa, Goodpasture syndrome, sterility disease, chronic active hepatitis, pemphigus, autoimmune thrombopenic purpura, and autoimmune hemolytic anemia.

[0012] The part that recognizes human PD-1 in the present invention has only to be a substance that recognizes human PD-1, for example, anti-human PD-1 antibody or a fragment thereof, human PD-1 itself or a fragment thereof, a ligand for human PD-1 or a fragment thereof (Freeman, GJ, et al., *Journal of Experimental Medicine*, 19, 7;1027-1034 (2000)), human PD-L2, and human PD-H3 etc.), and a low molecular weight organic compounds etc.

[0013] The antibody for human PD-1 or a fragment thereof may be either of complete polyclonal or monoclonal antibody, humanized antibody, complete human antibody, and short antibody thereof (for example, F(ab')₂, Fab', Fab, Fv) etc. which contains anti-human PD-1 antibody or a fragment thereof.

[0014] Concretely, they are monoclonal anti-human PD-1 antibodies produced by hybridomas (International Trust Number FERM P-19162) that had been deposited to National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary in Central 6, 1-1-1 Higashi, Tsukliba, Ibaraki, Japan at Dec 19, 2002, and had been transferred to International Deposit at June 5, 2003 (International Trust Number FERM BP-8392), which was named J110. Though F(ab')₂, Fab', Fab, and Fv antibody fragments of these antibodies etc. are preferable, they don't limit to them.

[0015] F(ab')₂, Fab', Fab, and Fv antibody fragments can be obtained by processing complete antibodies with protease enzyme, and optionally reducing it. They can be produced as antibodies, fragments of thereof, or fusion proteins with another proteins and the fragments, by using the expression vector made by gene rearrangement using the cDNA separated from antibody-producing hybridoma.

[0016] The membrane protein on cell membrane of human PD-1-expressing cells means the membrane protein that expresses on cell membrane of the same cell as human PD-1-expressing cells, and includes each the membrane protein of human PD-1-expressing human first stage culture cells or human cell lines. For example, T cell receptor complex or B cell receptor complex is preferable.

[0017] The part that recognizes the membrane protein on cell membrane of human PD-1-expressing cells may be a substance that recognizes the membrane protein that expresses on cell membrane of the same cell as human PD-1-expressing cells, and includes, for example, antibodies against the membrane protein and fragments thereof, the membrane protein itself and fragments thereof, ligands for the membrane protein and fragments thereof, and low molecular weight organic compounds that bind to the membrane protein etc.

[0018] The antibodies or partial fragments thereof to the membrane protein on cell membrane of human PD-1-expressing cells are antibodies or partial fragments thereof to the membrane protein that expresses on cell membrane of the same cell as human PD-1-expressing cells, and may be either of complete polyclonal or monoclonal antibodies, humanized antibodies, complete human antibodies, and short antibodies thereof (for example, F(ab')₂, Fab', Fab, Fv) etc.

[0019] T cell receptor complex is at least a complex comprising T cell receptor consisting of α subunit and β subunit and CD3 consisting of γ subunit, δ subunit, ϵ subunit, and ζ subunit.

[0020] B cell receptor complex is at least a complex comprising membrane-bound immunoglobulin, CD79 α subunit, and CD79 β subunit.

[0021] The antibodies or partial fragments thereof to T cell receptor complex may be either of antibodies or partial fragments thereof that recognize T cell receptor complex. They include antibodies or partial fragments thereof to each subunit of T cell receptor and CD3, which composes T cell receptor complex and may be either of complete polyclonal or monoclonal antibodies, humanized antibodies, complete human antibodies, and short antibodies thereof (for example, F(ab')₂, Fab', Fab, Fv) etc. For example, the monoclonal antibodies against CD3 can be produced by using hybridoma that has already been established. Anti-CD3 (α -CD3emAb (PharMingen, Inc.)) can be bought.

[0022] The antibodies or partial fragments thereof to B cell receptor complex may be either of antibodies or partial fragments thereof that recognize B cell receptor complex. They include antibodies or partial fragments thereof to each

subunit of membrane-bound immunoglobulin and CD79, which composes B cell receptor complex, and may be either of complete polyclonal or monoclonal antibodies, humanized antibodies, complete human antibodies, and short antibodies thereof (for example, F(ab')₂, Fab', Fab, Fv) etc. Concretely, commercial anti-BCR antibodies can be used and, for example, anti-IgG (H+L) polyclonal antibodies can be bought (Zymed Laboratories).

5 [0023] The substance comprising the part that recognizes human PD-1 and the part that recognizes the membrane protein on cell membrane of human PD-1-expressing cells means a substance that can simultaneously bind to an extracellular domain of human PD-1 and an extracellular domain of the membrane protein on cell membrane of the same cell. Concretely, they include bispecific antibodies comprising specific antibodies or fragments thereof to human PD-1 and specific antibodies or fragments thereof to the membrane protein on cell membrane of human PD-1-expressing cells.

10 [0024] The bispecific antibodies are unsymmetrical antibodies having two independent antigen-recognition sites with two different antigenic specificities. A well-known chemical method (Nisonoff, A., et al., *Archives of Biochemistry and Biophysics*, 90;460-462 (1961), Brennan, M., et al, *Science*, 299;81-83 (1985)) is already well-known as a preparation method of the bispecific antibodies. The bispecific antibodies can be obtained by respectively hydrolyzing two kinds of antibodies by enzyme and cutting disulfide bonds of the H chains by reducing agents, and then mixing and reoxidizing the different kind of antibodies. Recently, the preparation method using cross linking agents such as glutaraldehyde and carbodiimide has been disclosed (JP02-01556).

15 [0025] Technologies that directly produce the bispecific antibodies by using gene recombination technologies have been known. For example, the producing of bispecific antibodies (called single chain diabody.) to carcinoembryonic antigen and *E. coli* beta-galactosidase has been reported in Alt, *FEBS Letter*, 454, 90 (1999). A heavy chain variable domain (VH) and other light chain variable domain (VL) of the fragment are connected with linkers to make them combine between two continuous domains on the same chain. A heavy chain variable domain (VH) and other light chain variable domain (VL) of the fragment are connected with linkers to make them combine between two continuous domains on the same chain. Therefore, VH and VL domain of the fragment are unavoidable to combine with complementary VL and VH domain of another fragment, as a result, two antigen binding sites are formed. Though 3-12 amino acid residues are preferable for the peptide linkers, the sequence is not limited (Hudson, PJ., et al, *Journal of Immunology Medicine*, 231, 1-2; 177-189 (1999)).

20 [0026] As manufacturing of the bispecific antibodies using hybridomas, there is Reading, et al's method, that is, a method of producing hybrid hybridomas by further fusing two kinds of hybridomas that produce the monoclonal antibodies and then selecting hybrid hybridomas that produce target bispecific antibodies (US4474893).

25 [0027] The bispecific antibodies comprising specific antibodies or fragments thereof to human PD-1 and specific antibodies or fragments thereof to the membrane protein on cell membrane of human PD-1-expressing cells are antibodies that can simultaneously bind to the extracellular domain of human PD-1 and the extracellular domain of the membrane protein on cell membrane of the same cell.

30 [0028] The bispecific antibodies can be produced by the following method;

- (1) animals are sensitized by human PD-1 or human membrane protein as an immunogen,
- (2) splenic cells from the sensitized animals and myeloma cells from syngeneic animals are fused,
- (3) cells that produce monoclonal antibodies against the sensitizing antigen (human PD-1 or human membrane protein) are screened from the obtained hybridomas,
- 40 (4) target antibodies-producing hybridomas are cloned,
- (5) the cloned antibodies-producing hybridomas are proliferated,
- (6) the produced antibodies are separated and refined,
- (7) the bispecific antibodies are produced by cross-linking the obtained anti-human PD-1 antibodies and anti-human membrane protein antibodies with linkers, or
- 45 (8) they are further digested by pepsin and are separated, and refined to obtain F(ab')₂,
- (9) each prepared F(ab')₂ is reduced and is separated and refined,
- (10) the bispecific antibodies can be produced by cross-linking each prepared Fab_{SH} by linkers.

50 The linkers are not limited and may be anything that can link the part that recognizes the membrane protein of PD-1-expressing cells to the part that recognizes human PD-1, keeping an appropriate range. More concretely, they include peptides and amides etc.

The commercial products, for example, phenylenedimaleimide (Aldrich) can be used as the linkers.

When both or one of substances that respectively recognize the membrane protein of PD-1-expressing cells and human PD-1 is/are low-molecular weight organic compound(s),

55 (11) using the antibodies produced by the above technique, the low-molecules that inhibit a bond between human membrane protein or human PD-1 and each antibody are found by measuring with a suitable detector,

(12) the antibody can be produced by cross-linking the low-molecules, the antibodies, or the Fab with linkers.

[0029] It concretely explains each process as follows.

[0030] (1) In sensitization, it is preferable that human PD-1 or human membrane protein is administrated to peritoneal cavity or foot pad of sensitized animals. And, the sensitized animals have only to be animals such as mouse and rat etc. that the monoclonal antibody can be obtained in general and are not limited. For example, it is enough that 10-200 µg of the antigen are administrated to mouse once.

[0031] A spleen of the sensitized animal that antibody titer has risen enough among the sensitized animals in previous (1) is removed. Suspension of the splenic cells is prepared according to the usual manner. Then, cell fusion of previous (2) is performed by adding polyethylene glycol (preferably PEG4000.) to the mixture with the obtained splenic cells and syngeneic myeloma cells at 37°C. Several kinds such as P3×63Ag8, P3/NS1/1-Ag4-1, and SP-2/0-Ag-14 are known as mouse myeloma cells, and everything are obtained easily.

[0032] It is preferable that myeloma cells are HGPRT (hypoxanthine-guanine phosphoribosyltransferase)- cell lines that can not live in HAT media (a medium containing hypoxanthine, aminopterin, and thymidine), and don't secrete antibodies. SP-2/0-Ag-14 are preferably used.

[0033] Then, the obtained cell fusion mixtures are sown in 96 microwell plate at low density, which are cultured in HAT medium. By 1-2 weeks, unfused myeloma cells, hybridomas of myeloma cells, unfused splenic cells; and hybridomas of splenic cells die out, whereas only hybridomas of splenic cells and myeloma cells proliferate.

[0034] By reacting culture supernatant of hybridomas with solid phase antigens and measuring the antibodies that specifically adsorbs the antigens by using labeled second antibodies, screening of previous (3) judges whether hybridomas product the antibodies against human membrane protein or human PD-1 or not.

[0035] The process of (4) is performed by cloning antibody-producing hybridomas according to soft agar culture (*Monoclonal Antibodies*, 372 (1980)). In this case, it is also possible to use the limiting dilution.

[0036] In the process of (5), to obtain a large amount of antibody more efficiently, a method of administrating the hybridomas into mouse peritoneal cavity, and separating and refining them from peritoneal fluid can be used.

[0037] In the process of (6), usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. are used, and more effectively, affinity chromatography using protein A-sepharose CL-4B (Amersham Biosciences K.K.) can be used.

[0038] Since the bispecific antibodies of the present invention specifically bind, they can be used for purification and concentration such as affinity chromatography etc. of human PD-1.

[0039] In the process of (7), for example, cross linking agents can make sulfo-EMCS (N-(6-maleimidemdecaproxy) succinimide sodium salt) bind to SH (mercapto) groups or amide groups of antibodies. First, either of antibodies is referred to amido coupling reactions with sulfo-EMCS. The unreacted sulfo-EMGS is separated by gel filtration. SH (mercapto) groups of the other antibody that have been reduced by 2-mercaptoproethylamine etc. are referred to react with maleimide groups of sulfo-EMCS that have bound to the first antibody. The one that two kinds of antibodies were mutually cross-linked is separated by gel filtration.

[0040] In the process of (8), each antibody that be obtained in process (6) was digested by pepsin for 48 hours at 37°C. F(ab')₂ digested by pepsin are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. and more effectively, gel filtration using cefaclor S-200 (Amersham Biosciences K.K.) can be used.

[0041] In the process of (9), F(ab')₂ are reduced by 2-mercaptoproethylamine for 30 minutes at 30°C. The reduced Fab_{SH} are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. and more effectively, gel filtration using cefaclor S-200 can be used.

[0042] In the process of (10), the other antibodies in Fab_{SH} fraction are referred to bind with linkers. Cross linking agents have only to bind mercapto (SH) groups of Fab_{SH}, which is referred to react with phenylenedimaleimide for 30 minutes at room temperature. Then, it is referred to react with 1.3 times more the other Fab_{SH} for 4 hours at room temperature. The obtained substance having bivalent specificity are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc. and more effectively, gel filtration using cefaclor S-200 can be used.

[0043] In the process of (11), the antibodies obtained in process (6) can be used as they are, or as the one that are preferably labeled (for example, biotin-labeling and FITC-labeling etc.) by the common procedure. In ELISA, the antibodies are added to solid phase antigens. Then, when using enzyme-labeled secondary antibody and biotin-labeled antibody, the specific binding between the antibodies and the antigens can be measured by absorptiometer under the presence of chromophore substance, after adding enzyme-labeled streptavidin. Low-molecules that specifically recognize PD-1 or the membrane protein can be obtained by using this assay system.

[0044] In the process of (12), when the other is an antibody or Fab, it can bind to an antibody or Fab by introducing suitable functional groups to the obtained low-molecules. For example, if maleimide groups are introduced, it can bind to mercapto (SH) groups of the antibody or Fab. If both are low-molecules, molecules including both can be synthesized.

[0045] On the other hand, cDNA of each antibody can be separated from hybridomas that produce the monoclonal antibodies against each antigen. By transforming suitable host cells using expression vector containing DNA that both

cDNA or partial fragments thereof have been linked by gene recombination methods, the host cells can produce bispecific antibodies.

5 [0046] Concretely, the bispecific antibodies comprising the antibodies against human PD-1 or partial fragments thereof and the antibodies against the membrane protein on cell membrane of human PD-1-expressing cells or partial fragments thereof can be prepared by the following methods;

- (1) Each antibody gene is separated from each hybridoma that anti-human PD-1 monoclonal antibodies and anti-membrane protein monoclonal antibodies are respectively produced,
- 10 (2) Variable region DNA of anti-human PD-1 monoclonal antibody gene and variable region DNA of anti-membrane protein monoclonal antibody gene are linked by using linker DNA. The expression vectors containing the linked DNA fragments are introduced to suitable host cells,
- (3) the cells are cultured under a suitable culture condition, and produced proteins are separated and refined.

15 [0047] Each process is concretely explained as follows.

[0048] The process of (1) comprises a process of separating RNA from hybridomas and a process of separating an antibody gene or cDNA encoding partial peptide thereof.

[0049] The process of separating the total RNA or mRNA from hybridomas can be performed according to a well-known method (a method described in Sambrook, J., et al, *Molecular Cloning* (1989), Cold Spring Harbor Laboratory, or F. M. Ausubel., et al., *Current Protocol in Molecular Biology*).

20 [0050] By using synthetic DNA primers having partial nucleotide sequences of the antibodies of the present invention, cDNA encoding the antibody genes of the present invention or partial peptide thereof can be amplified by Polymerase Chain Reaction (hereafter, called PCR). Or, by hybridization with probes labeled by using DNA fragments or the synthetic DNAs encoding a part or whole region of the antibodies of the present invention, the cDNA can be selected from cDNA contained in suitable vectors. The hybridization can be performed according to a well-known method. The antibody gene can be amplified by using the total RNA or mRNA by Reverse Transcriptase Polymerase Chain Reaction (Hereafter, called RT-PCR).

25 [0051] (2) As a method of producing the bispecific antibodies of the present invention,

- 30 (i) a method of synthesizing peptide and
- (ii) a method of producing by gene recombination technologies etc. are enumerated, and the method of the described in (ii) is preferable, industrially.

[0052] The expression system (hosts-vector system) to produce peptide by using gene recombination technologies includes, for example, the expression system of bacillus, yeasts, insect cells, and mammalian cells.

35 [0053] The vector system includes *E. coli* plasmids (for example, pBR322, pBR325, pUC12, and pUC13), *Bacillus subtilis* plasmids (for example, pUB110, pTP5, and pC194), yeast plasmids (for example, pSH19 and pSH15), bacteriophages such as lambda phage, animal viruses such as retrovirus, vaccinia virus, and baculovirus, PA1-11, pXT1, pRc/CMV, pRc/RSV, and pcDNA1/Neo etc.

40 [0054] The promoter in the present invention has only to be an appropriate promoter corresponding to the gene expression host. For example, when animal cells are used as hosts, SR α promoter, SV40 promoter, LTR promoter, CMV promoter, and HSV-TK promoter etc. are enumerated. It is preferable to use CMV (cytomegalovirus) promoter, SR α promoter etc. In case of *Escherichia coli*, trp promoter, lac promoter, recA promoter, λ PL promoter, lpp promoter, and T7 promoter etc. are preferable. In case of *Bacillus* bacterium, SPO1 promoter, SPO2 promoter, and penP promoter etc. are preferable. In case of yeasts, PHO5 promoter, PGK promoter, GAP promoter, and ADH promoter etc. are preferable.

45 [0055] Additionally, the expression vector containing enhancer, splicing signal, polyA signal, selected marker, and SV40 duplication ori (hereafter, it may be called SV40ori.) etc. can be used, if necessary. The selected marker includes, for example, dihydrofolate reductase (hereafter, it may be called dhfr.) gene (Methotrexate (MTX) resistance), ampicillin resistance gene (hereafter, it may be called Ampr), and neomycin resistance gene (hereafter, it may be called Neo. G418 resistance) etc. Especially, when dhfr gene is used as a selected marker using dhfr gene deficient chinese hamster cells, a target gene can be selected even by using the medium without thymidine. The signal sequence to suitable for the hosts can be added to N-terminal side of the protein of the present invention, if necessary. When the hosts are *Escherichia*, PhoA signal sequence and OmpA signal sequence etc. can be used. When the hosts are bacillus, α -amylase signal sequence and subtilisin signal sequence etc. can be used. When the hosts are bacillus, MF α signal sequence, SUC2 signal sequence etc. can be used. When the hosts are animal cells, α -insulin signal sequence, α -interferon signal sequence, and antibody signal sequence etc. can be used, respectively. The transformants can be manufactured using the vector containing DNA encoding the constructed protein of the present invention.

55 [0056] By culturing *Escherichia* transformed with the expression vector in suitable medium, the target peptide is

obtained from the body cells. And, if a signal peptide (for example, a signal peptide of *pelB*) of bacteria is used, the target peptide is secreted in the periplasm. Further, it can be produced as fusion protein with other peptide. In case of the expression in mammalian cells, for example, by culturing mammalian cells transformed by suitable expression vectors including cDNA encoding a target protein in suitable medium, the target peptides are secreted into medium.

[0057] For example, *Escherichia*, *Bacillus* bacterium, yeasts, insect cells, insects, and animal cells etc. can be used as host cells. For example, *Escherichia coli* K12, DH1, JM103, JA221, HB101, C600, JM109, DH5, and DH5 α etc. can be used as concrete examples of *Escherichia*. For example, *bacillus Bacillus subtilis* MI114 etc. can be used as *Bacillus* bacterium. For example, *Saccharomyces cerevisiae* AH22, AH22R - NA87-11A, DKD-5D, or 20B-12, *Saccharomyces pombe* NCYC1913, or NCYC2036, and *Pichia pastoris* KM71 etc. can be used as yeasts. When virus is AcNPV, for example, *Spodoptera frugiperda* Cell (SF cell), MG1 cells derived from *Trichoplusia ni* midgut, High FiveTM cells derived from *Trichoplusia ni* egg, cells derived from *Mamestra brassicae*, cells derived from *Estigmene acrea* etc. can be used as insect cells. When virus is BmNPV, cell lines derived from silkworm (Bombyx moriN cells; BmN cells) etc. can be used. For example, Sf9 cells (ATCC CRL1711) (Vaughn, J. L., *In Vivo*, 13; 213-217 (1977)) and Sf21 cells etc. can be used as Sf cells. For example, silkworm larvae etc. can be used as insects. For example, COS-1, COS-7, Vero, chinese hamster cell CHO (hereafter, it's abbreviated with CHO cells.), dhfr-deficient chinese hamster cell CHO (hereafter, it's abbreviated with CHO(dhfr-) cells), mouse L cells, mouse AtT-20, mouse myeloma cells, rat GH3, HEK293 T lymphocytes, and human FL cells etc. can be used as animal cells. For example, *Escherichia* transformation can be performed according to *Proc. Natl. Acad. Sci. (USA)*, 69, 2110 (1972). For example, *Bacillus* transformation can be performed according to *Molecular & General Genetic*, 168, 111 (1979). For example, yeasts transformation can be performed according to Becker, DM., et al, *Methods in Enzymology*, volume 194, p.182-187 (1991), or *Proc. Natl. Acad. Sci. (USA)*, 75, 1929 (1978). Insect cells or insects transformation can be performed according to *BioTechnology*, 6; 47-55 (1978). Animal cells transformation can be performed according to *CELL TECHNOLOGY SUPPLEMENT 8 NEW CELL TECHNOLOGY EXPERIMENTAL PROTOCOL*, Shujunsha, 263 (1995), or *Virology*, 52, 456 (1973).

[0058] (3) The obtained peptides are purified by usual methods such as salting out, ion-exchange chromatography, gel filtration, hydrophobic chromatography, and affinity chromatography etc.

[0059] In general, a substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide containing the amino acid sequence that is 90% or more, 95, 98, or 99% or more homologous to the polypeptide on producing.

[0060] A homologue of the substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide containing the amino acid sequence that is at least 70% or more, preferably at least 80, 90, or 95% or more homologous to the polypeptide over a region of at least continuous 20 amino acids, preferably at least 30, 40, 60, or 100 amino acids.

[0061] A fragment of the substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide containing at least 10 amino acids, preferably at least 15, 20, 25, 30, 40, 50, or 60 amino acids, and a homologue thereof is a polypeptide containing the amino acid sequence that is at least 70%, preferably at least 80, 90, or 95% or more homologous to the polypeptide over a region of at least continuous 10 amino acids, preferably at least continuous 15, 20, 25, 30, 40, 50, or 60 amino acids.

[0062] A substantially pure polypeptide comprising amino acid sequence that deleted one or several amino acids from a polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide comprising amino acid sequence that deleted one or two amino acids or more (preferably 1 to approx. 25, more preferably 1 to approx. 10, furthermore, preferably 1 to 5) from amino acid sequence.

[0063] A substantially pure polypeptide comprising amino acid sequence that has been substituted by one or several amino acids from a polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:11 is a polypeptide comprising amino acid sequence that has been substituted by one or two amino acids or more (preferably 1 to approx. 25, more preferably 1 to approx. 10, furthermore, preferably 1 to 5).

[0064] A homologue of a polynucleotide comprising DNA the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:9 is a polynucleotide that is at least 70%, preferably at least 80, 90, or more preferably 95% or more homologous to the polynucleotide over a region of at least continuous 20, preferably at least continuous 30, 40, 60, or 100 nucleotide sequence.

[0065] A fragment of the polynucleotide comprising DNA the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:9 is a polynucleotide containing polynucleotide comprising at least continuous 20, preferably at least continuous 30, 40, 50, 60, or 100 nucleotide sequence.

[0066] A DNA hybridizing to DNA containing the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:9 under stringent condition includes, for example, approx. a DNA containing nucleotide sequence that is approx. 70% or more, preferably approx. 80% or more, more preferably approx. 90% or more, most preferably approx. 95% or more homologous to nucleotide sequence respectively represented by SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:9.

[0067] The hybridization can be performed according to a well-known method or, for example, a method described

in J. Sambrook, *Molecular Cloning*, 2nd, Cold Spring Harbor Laboratory. When using a commercial library, it is possible to perform it according to an attached method described in directions for use. More preferably, it is possible to perform it under stringent condition. High-stringent condition is approx. 19-40 mM, preferably approx. 19-20 mM of NaCl concentration, at approx. 50-70°C, preferably approx. 60-65°C. Approx. 19 mM of sodium concentration at approx. 65°C is most preferable, especially.

5 Industrial applicability

10 Application to medicine:

[0068] The substance specific to human PD-1 of the present invention can be used for therapy and/or prevention for the following disease.

[0069] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for neurodegenerative diseases (geropsychosis, Alzheimer disease, Down syndrome, Parkinson's disease, Creutzfeldt-Jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt-Creutzfeldt-Jakob disease).

[0070] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for diseases that accelerate the immune reaction, for example, autoimmune diseases (glomerular nephritis, arthritis, dilated cardiomyopathy-like disease, ulcerous colitis, Sjogren syndrome, Crohn disease, systemic erythematoses, chronic rheumatoid arthritis, multiple sclerosis, psoriasis, allergic contact dermatitis, polymyositis, pachyderma, periarteritis nodosa, rheumatic fever, vitiligo vulgaris, insulin dependent diabetes mellitus, Behcet disease, Hashimoto disease, Addison disease, dermatomyositis, myasthenia gravis, Reiter syndrome, Graves' disease, anaemia perniciosa, Good-pasture syndrome, sterility disease, chronic active hepatitis, pemphigus, autoimmune thrombopenic purpura, and autoimmune hemolytic anemia).

[0071] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for collagenosis (systemic lupus erythematosus, rheumatoid arthritis, systemic scleroderma, diffuse scleroderma, dermatomyositis, polymyositis, polymyositis, Sjogren's syndrome, mixed connective tissue disease, polyarteritis nodosa, and rheumatic fever etc.).

[0072] The substance specific to human PD-1 of the present invention is useful for therapy and/or prevention for organ graft rejection, allergic disease, and diseases caused by attenuation of immune reaction, which PD-1 participates, for example, tumour and infectious disease.

[0073] When using the substance specific to human PD-1 of the present invention for the above purpose, it is usually administered systemically or locally, and orally or parenterally.

[0074] The dosage is different depending on age, body weight, symptom, therapeutic effect, administration route, and duration of the treatment etc. For oral administration, generally, the dosage range from 0.1 mg to 100 mg per an adult is orally administered once to several times per day, or the dosage range from 0.01 mg to 30 mg per an adult is administered once to several times per day parenterally, suitably intravenously, and is intravenously administered for 1 to 24 hours per day continuously.

[0075] Since the dosage changes depending on various conditions as described above, there are cases in which doses lower or greater than the above dosage may be used.

[0076] When a composition of the present invention is administered, it is used as internal solid medicines and internal liquid medicines for internal use, and injections, external preparations, suppositories etc. for parenteral administration.

[0077] The internal solid medicines for oral administration include compressed tablets, pills, capsules, dispersing powders, granules etc. The capsules include hard capsules and soft capsules.

[0078] In case of such the solid medicines, one or more active compound(s) may be pharmaceutically manufactured as itself/themselves or a formulation with excipients (lactose, mannitol, glucose, microcrystal cellulose, and starch etc.), binders (hydroxypropylcellulose, polyvinyl pyrrolidone, and magnesium metasilicate aluminate etc.), disintegrators (cellulose calcium glycolate etc.), lubricants (magnesium stearate etc.), stabilizers, or solubilizers (glutamate and aspartic acid etc.) etc. according to usual methods. Further, they may be optionally coated by coatings (sucrose, gelatin, hydroxypropylcellulose, and hydroxypropylmethylcellulose phthalate etc.) or coated in the layer of two or more. Further, capsules of absorbable materials such as gelatin may be included.

[0079] The liquid compositions for oral administration include pharmaceutically acceptable waters, suspensions, emulsions, syrups, and elixirs etc. As to such liquid medicines, one or more active compound(s) may be dissolved, suspended, or emulsified to generally used diluent (purified water, ethanol or those mixing liquids etc.). Further, those liquid medicines may contain humectants, suspending agents, emulsifying agents, sweeteners, flavor agents, flavoring agents, preservatives, and buffers etc.

[0080] The injections for parenteral administration include solid injections that are dissolved or suspended to solution, suspension, emulsion, or time of use solvent. The injections are used by dissolving, levigating and melting one or more

activator(s) to the solvent. As the solvent, for example, water for injection, distilled saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol etc. and these combinations are used. Further, this injection may include stabilizers, solubilizers (glutamate, aspartic acid, and polysorbate 80 (registered trademark) etc.), suspending agents, emulsifying agents, soothing agents, buffers, and preservatives etc. These are sterilized in the final process or are manufactured from the aseptic manipulation. Aseptic solid medicines may be manufactured as a freeze-drying product and may be used by making to be aseptic or dissolving to aseptic distilled water for injection or other solvents before use.

[0081] Other compositions containing one or more activator(s) for parenteral administration include liquid for external use, ointment drug, coating drug, inhalant, aerosol, suppository and pessary for intrarectal administration which is prescribed according to a routine procedure.

[0082] The sprays may contain a stabilizer such as sodium hydrogen sulfite besides the diluent generally used, a buffer giving isotonicity, and an isotonic medicine such as, for example, sodium chloride, sodium citrate, or citrates. Production methods of the sprays have been described in, for example, U.S. Patent 2,868,691 specification and U.S. Patent 3,095,355 specification in detail.

[0083] Since PD-1 relates to the immune reaction, PD-1 can also be used for screening etc., the substance related to the immune reaction by measuring the expression of human PD-1 using the substance specific to human PD-1 of the present invention.

[0084] The substance specific to human PD-1 of the present invention comprises of a part that recognizes human PD-1, a part that recognizes the membrane protein on cell membrane of human PD-1-expressing cells, and a linker, and is an excellent substance that specifically recognizes human PD-1 and the membrane protein, and can transmit human PD-1 signal.

Brief Description of Drawings

[0085]

Figure 1 shows the construction of a bispecific antibody expression vector.

Figure 2 shows the reactivity of each bispecific antibody against X63 cell surface antigen expressed in CD3(-)/PD-1(+) cells and peripheral blood mononuclear cells (PBMC) surface antigen as CD3(+)/PD-1(-) cells. In this figure, filling areas of histogram represent control IgG and opening areas represent distribution of PD-1 or CD3 positive cell.

Figure 3 shows the effect on proliferative response of activated human peripheral blood T cells of bispecific antibody. In this figure, "-" represents Control IgG-adding group and "BsAb" represents the bispecific antibody-adding group, the spindle represents measurement absorbance, and ** represents P<0.05 in significance test.

Best Mode for Carrying out the Invention

[0086] The following examples explain the present invention more concretely, but don't limit the range of the present invention.

Example 1:

[0087] To obtain DNA encoding anti-human PD-1 antibody and anti-human CD3 antibody respectively, each total RNA was isolated from J110 (International Trust Number: FERM BP-8392) hybridoma and CD3 antibody hybridoma (obtained from ATCC : ATCC Number: CRL-8001). The operation was performed by using SV total Isolation System (trade name: purchase from Promega) according to the manufacturer instructions.

[0088] J110 hybridoma cDNA library and CD3 antibody hybridoma cDNA library were generated from total RNA (total RNA) by oligo dT prime method by using Ready-To-Go You-Prime First-Strand Beads (trade name: purchase from Amersham Pharmacia). The operation and procedure were done according to the manufacturer instructions.

[0089] cDNA of variable region of each IgG heavy chain and IgG light chain of anti-human PD-1 antibody and anti-human CD3 antibody was amplified by PCR reaction using Heavy Primers and Light Primers (the trade name: purchase from Amersham Pharmacia), respectively. PCR was carried out the following steps; as a first step at 95°C for 2 minutes and as cycle steps at 95°C for 30 seconds, at 50°C for 30 seconds, and at 72°C for 40 seconds was repeated 30 times and was left at 72°C for 5 minutes as last step.

[0090] PCR product was separated by agarose gel electrophoresis. The expected size of DNA fragment was collected and was cloned into pGEM-T Easy Vector (trade name: purchase from Promega). Then, *E. coli* DH5 α was transformed with the plasmid. DNA of each IgG heavy chain (SEQ ID NO:1 or 5) and IgG light chain (SEQ ID NO:3 or 7) were sequenced to determine the consensus sequence.

Example 2:

[0091] DNAs encoding bispecific antibodies were prepared by being respectively connected to the separated cDNAs in example 1. Fragment 1 was prepared by connecting IgG heavy chain cDNA (SEQ ID NO:1) of anti-human PD-1 antibody and IgG light chain cDNA (SEQ ID NO:7) of anti-human CD3 antibody by PCR using linker No.1 (SEQ ID NO:19), linker No.2 (SEQ ID NO:20), primer No.1 (SEQ ID NO:14), and primer No.2 (SEQ ID NO:15) (Figure 1). Fragment 2 was prepared by connecting IgG heavy chain cDNA (SEQ ID NO:7) of anti-human CD3 antibody and IgG light chain cDNA (SEQ ID NO:1) of anti-human PD-1 antibody by PCR using linker No.3 (SEQ ID NO:21), linker No.4 (SEQ ID NO:22), primer No.3 (SEQ ID NO:16), and primer No.4 (SEQ ID NO:17) (figure.1). Fragment 3 was prepared (Figure 1) by connecting fragment 1 and fragment 2 by PCR using linker No.5 (SEQ ID NO:23), linker No.6 (SEQ ID NO:24), primer No.5 (SEQ ID NO:18), and primer No.4 (SEQ ID NO:22) and then the nucleotide sequence was decided (SEQ ID NO:9).

[0092] Each PCR reaction was respectively performed. First PCR was performed by repeating 20 times the following steps; at 94°C for 30 seconds, at 40°C for 30 seconds, and at 72°C for 50 seconds. 2nd PCR was performed by repeating 30 times the following steps; at 94°C for 30 seconds, at 50°C for 30 seconds, and at 72°C for 50 seconds, by using first PCR solution as a template.

Primer No.2:

20 5'-TTTTTTAAGCTTACAGGTCCAGCTGCAGGAGTCA-3' (SEQ ID NO:14)

Primer No.2:

25 5'-TTTTTTGC GGCCGCCCGTTATTTCCAACTTTG-3' (SEQ ID NO:15)

Primer No.3:

30 5'-TTTTTTAAGCTTACAGGTCCAGCTGCAGCAGTCT-3' (SEQ ID NO:16)

Primer No.4:

35 5'-TTTTTTGC GGCCGCCCGTTGATTCCAGCTTGG-3' (SEQ ID NO:17)

Primer No.5:

40 5'-ATGAACTGGTACCAGCAGAAG-3'(SEQ ID NO:18)

Linker No.1:

45 5'-AGGGACCACGGTCACCGTCTCCTCAGGTGGAGGC GGTTACAAATTGTT
50 CTCACCCAGTCTCCAG-3' (SEQ ID NO:19)

55 Linker No.2:

5' -CTGGAGACTGGGTGAGAACATTGTGAACCGCCTCCACCTGAGGAGAC
 5
 GGTGACCGTGGTCCCT-3' (SEQ ID NO:20)

10 Linker No.3:

5' -AGGCACCACTCTCACAGTCTCCTCAGGTGGAGGCAGGTCAGACATCCAG
 15 ATGACCCAGTCTCCAG-3' (SEQ ID NO:21)

Linker No.4:

20 5' -CTGGAGACTGGTCATCTGGATGTCTGAACCGCCTCCACCTGAGGAGAC
 TGTGAGAGTGGTGCCT-3' (SEQ ID NO:22)

25 Linker No.5:

5' -GGGGACAAAGTTGAAATAAACCGGGGTGGAGGCAGGTCAGGCGGAGGT
 30 GGCTCTGGCGGTGGCGGATCGCAGGTCCAGCTGCAGCAGTCTGGGG-3' (SEQ ID
 NO:23)

35 Linker No.6:

5' -CCCCAGACTGCTGCAGCTGGACCTGGATCCGCCACGCCAGAGCCACC
 40 TCCGCCTGAACCGCCTCCACCCGGTTATTCACCAACTTGTCCCC-3' (SEQ ID
 NO:24)

45 [0093] DNA encoding the bispecific antibody prepared by the above method was cloned into expression vector pSecTag2/HygroA (trade name: purchase from Invitrogen). First, each of fragment 1 and fragment 3 was digested by restriction enzyme *Hind*III, *Kpn*I, *Kpn*I, and *Not*I and then was purified by agarose electrophoresis. Then, the DNA fragments were ligated in a *Hind*III and *Not*I digested pSecTag2/HygroA vector. *E. coli* DH5 α was transformed with the plasmid J110-CD3scDb-pSec/hygroA encoding the bispecific antibody was amplified, extracted, and purified (Figure 1).

50 Example 3:

55 [0094] Bispecific antibody protein was prepared by J110-CD3scDb-pSec/hygroA expression plasmid. The construct was transiently transfected into human kidney cell line 293T (ATCC Number: CRL-11268) with LipofectAMINE-plus (trade name: purchased from Invitrogen) and cultured for four days. The supernatant was sterilized with 0.22 μ m PVDF filter, and was concentrated using 40% PEG20000 solution. The concentrated supernatant was purified by HiTrap Chefating HP column (trade name: purchased from Amershampharmacia).

Example 4:

[0095] The reactivity of the bispecific antibody (PD-1 and CD3) binding to cell surface antigens analyzed by FACScan.
[0096] 5 1 or 10 µg of the bispecific antibodies were respectively added to human PD-1-expressed X63 cell lines as PD-1 positive/CD3 negative cells (CD3(-)/PD-1(+) cells) and human peripheral blood mononuclear cells as PD-1 negative/CD3 positive cells (CD3(+)/PD-1(-) cells), and incubated on ice. Immediately second antibodies were added and incubate on ice for 30 min. It was confirmed that the bispecific antibodies reacted to PD-1 and CD3.

Example 5:

10 [0097] 10 The activity of the bispecific antibody was evaluated as an effect on the proliferation of activated human peripheral blood T cells.

[0098] 15 Concretely, PBMC were isolated from peripheral blood samples of healthy donors by Lymphoprep Tube (trade name: purchased from HYCOMED PHARMA). The operation and procedure were done according to the manufacturer instructions. Erythrocytes were removed from PBMC by lysis with lysis buffer (0.8% NH₄Cl, 0.1% KCO₃, 1 mM EDTA). And purified T cell passed through Nylon Fiber ColumnT (trade name: purchased from Rosh) were resuspended to medium (RPMI1640 medium including 10% fetal bovine serum).

[0099] 20 Purified T cell (2×10^6 /mL/well) were cultured for 60 hours with 1 µg/ml anti-human CD28 antibody (the clone name: CD28.2 and purchased from Pharmingen) in 24 well-plate that has were pre-coated with 5 µg/ml anti-human αβTCR antibody (the clone name: T10B9.1A-31 and purchased from Pharmingen). Activated T cells were rested for 12 hours, and resting T cells (1×10^6 /100 µl/well) were restimulated adding 1 µg/well of bispecific antibody in 96 well-plate that were pre-coated with 0.1 µg/ml anti-αβTCR antibody. 48 hours later, T cell proliferation was determined-by BrdU incorporation using Cell Proliferation ELISA (the trade name: purchased from Rosh). Figure 3 shows the result.

[0100] 25 The bispecific antibodies have significantly decreased the proliferation of the activated human peripheral blood T cells.

30

35

40

45

50

55

SEQUENCE LISTING

<110> ONO PHARMACEUTICAL CO., LTD.
HONJO, Tasuku

5 <120> Substances which specifically recognize human PD-1
<130> ONF-4846PCT
<150> JP 2003-14793
<151> 2003-01-23
<160> 26
<170> PatentIn version 3.1

10 <210> 1
<211> 357
<212> DNA
<213> Mus musculus

15 <400> 1
caggtccaggc tgccaggagtc aggacctggc ctggtaaac cttctcagtc tctgcccc
acctgcactg tcactggcca ctcaatcacc agtattatg cctggaaactg gatccggcag
tttccaggag acaaactggc gtggatggc tacataagct acagtggta cactaccc
aacccatctc tgaaaagtgc agtctctatc actcgagaca catccaagaa ccagtttcc
ctgcaggta attctgtgac tactgaggac acagccacat acttctgtgc aagagacctt
gattacggcc cctgggttgc ttactgggc caaggacca cggtcaccgt ctccctca 60
120
180
240
300
357

20 <210> 2
<211> 119
<212> PRT
<213> Mus musculus

25 <400> 2
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Ser Leu Ser Leu Thr Cys Thr Val Thr Gly His Ser Ile Thr Ser Asp
20 25 30
Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asp Lys Leu Glu Trp
35 40 45
Met Gly Tyr Ile Ser Tyr Ser Gly Tyr Thr Thr Tyr Asn Pro Ser Leu
50 55 60
Lys Ser Arg Val Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
65 70 75 80
Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Asp Leu Asp Tyr Gly Pro Trp Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser 115

35 <210> 3
<211> 324
<212> DNA
<213> Mus musculus

40 <400> 3
gacatccaga tgacccagtc tccagcctcc ctatctgcat ctgtgggaga aactgtcacc
ctcacatgtc gagcaagtga gaatattcac aattatttag catgttatca gcagaaacag
45 ggaaaatctc ctcagctcct ggtctataat gtaaaaacct tagcagatgg tgtgccatca 60
120
180
240
300
324
ggatccacca gtagtttta ctgtcaacat ttttgagta gtccgtggac gttcgggtgga
ggcaccaacg tgaaatcaa acgg

50 <210> 4
<211> 108
<212> PRT
<213> Mus musculus

55 <400> 4
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly

1	5	10	15	
	Glu Thr Val Thr Leu Thr Cys Arg Ala Ser Glu Asn Ile His Asn Tyr			
	20	25	30	
	Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val			
5	35	40	45	
	Tyr Asn Val Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly			
	50	55	60	
	Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro			
	65	70	75	80
10	Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser Ser Pro Trp			
	85	90	95	
	Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg			
	100	105		
15	<210> 5			
	<211> 357			
	<212> DNA			
	<213> Mus musculus			
20	<400> 5			
	cagggtccagc tgcagcagtc tggggctgaa ctggcaagac ctggggcctc agtgaagatg	60		
	tcctgcaagg cttctggcta caccttact aggtacacga tgcactgggt aaaacagagg	120		
	cctggacagg gtctggaatg gattggatac attaatccta gccgtggta tactaattac	180		
	aatcagaagt tcaaggacaa ggccacattg actacagaca aatcctccag cacagcctac	240		
	atgcaactga gcagcctgac atctgaggac tctgcagtct attactgtgc aagatattat	300		
	gatgatcatt actgccttga ctactggggc caaggcacca ctctcacagt ctccctca	357		
25	<210> 6			
	<211> 119			
	<212> PRT			
	<213> Mus musculus			
30	<400> 6			
	Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala			
	1 5 10 15			
	Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr			
	20 25 30			
	Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile			
	35 40 45			
	Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe			
	50 55 60			
35	Lys Asp Lys Ala Thr Leu Thr Asp Lys Ser Ser Ser Thr Ala Tyr			
	65 70 75 80			
	Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys			
	85 90 95			
	Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly			
	100 105 110			
40	Thr Thr Leu Thr Val Ser Ser			
	115			
45	<210> 7			
	<211> 321			
	<212> DNA			
	<213> Mus musculus			
50	<400> 7			
	caaattgttc tcacccagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc	60		
	atgacctgca gtgccagtc aagtgttaat tacatgaact gttaccagca gaagtcaggc	120		
	acctccccca aaagatggat ttatgacaca tccaaactgg cttctggagt ccctgcac	180		
	tccagggcgtt gttgggtctgg gacctttac tctctcacaa tcagcggcat ggaggctgaa	240		
	gatgctgcca cttattactg ccagcagttgg agtagtaacc cattcacgtt cggctcgaaa	300		
	acaaagtgg aaataaaccg g	321		
55	<210> 8			
	<211> 107			
	<212> PRT			
	<213> Mus musculus			

<400> 8
 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
 20 25 30
 5 Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
 35 40 45
 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg Gly Ser
 50 55 60
 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala Glu
 65 70 75 80
 10 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr
 85 90 95
 Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn Arg
 100 105

15 <210> 9
 <211> 1982
 <212> DNA
 <213> Artificial Sequence
 <223> Polynucleotide sequence coding bispecific antibody

20 <400> 9
 aatgggaggt tggggcgc cccaaatcaa cgggactttt caaaatgtcg taacaactcc 60
 gccccatgta cgccaaatggg cggtaggcgt gtacgggtgg aggtctatat aagcagagct 120
 ctctggctaa ctagagaacc cactgcttac tggcttatcg aaattaatac gactcaactat 180
 agggagaccc aagctggcta gccaccatgg agacagacac actcctgtca tgggtactgc 240
 tgctctgggt tccagggttcc actggtgacg cggcccagcc ggccaggcgc gccgtacgaa 300
 gcttacaggt ccagctgcag gagtcaggac ctggccttgt gaaaccttct cagtctctgt 360
 25 ccctcacctg cactgtcaact ggccactcaa tcaccagtga ttatgcctgg aactggatcc 420
 ggcagtttcc aggagacaaa ctggagtgga tgggtctacat aagctacagt gtttacacta 480
 CCTacaaccc atctctgaaa agtcgagctt ctatcaactcg agacacatcc aagaaccagt 540
 tcttcctgca gttgaattct gtgactactg aggacacagc cacatacttc tggcaagag 600
 accttgata cggccccctgg ttgtcttact ggggccaagg gaccacggc accgtctcc 660
 30 caggtggagg cggttcacaa attgttctca cccagtcctc agcaatcatg tctgcacatc 720
 Cagggggagaa ggtcaccatg acctgcagtg ccagctcaag tggtaagttac atgaactgg 780
 accagcagaa gtcaggcacc tcccccaaaa gatggattta tgacacatcc aaactggctt 840
 ctggagttccc tgctcaacttcc aggggcagtg ggtctgggac ctcttactct ctcacaatca 900
 gcggcatgga ggctgaagat gctgccactt attactgcac gcagtggagt agtaacccat 960
 tcacgttccg ctcggggaca aagttggaaa taaaccgggg tggaggcggcgt tcaggcggag 1020
 35 gtggcttcgg cgggtggcga tcgcagggtcc agctcgacg gtctggggct gaactggcaa 1080
 gacctggggc ctcagtgaag atgtccctgca aggctctgg ctacacctt actaggataca 1140
 cgatgcactg gttaaaacag aggccctggac agggtctggaa atggattgga tacattaatc 1200
 ctagccgtgg ttatactaattacaatcaga agttcaagga caaggccaca ttgactacag 1260
 acaaataatc cagcacagcc tacatgcacat tgagcagcct gacatctgag gactctgc 1320
 tctattactg tgcaagatataatgcattactgcct tgactactgg ggccaaaggca 1380
 40 ccactctcac agtctccctca ggtggaggcg gttcagacat ccagatgacc cagtctcc 1440
 cctccctatc tgcatctgtg ggaaaaactg tcacccctcac atgtcgagca agtgagaata 1500
 ttccacaattttttagcatgg tatcagcaga aacaggaaaa atctccctcag ctcctggct 1560
 ataatgtaaa aaccttagca gatgggtgtc catcaagggtt cagtggcagt ggatcaggaa 1620
 cacaatatttcc tctcaagatc aacagccctgc agcctgaaga ttttggggagt tattactgtc 1680
 aacattttttgg gatgtgtccg tggacgttcg gtggaggcac caagctggaa atcaaaacggg 1740
 Cggccgctcg aggagggccc gaacaaaaac tcacccatcaga agaggatctg aatagcggcc 1800
 45 tcgaccatca tcacccatcat cattgaggaa aaaccgcgtg atcagccctcg actgtgcctt 1860
 ctagttgcca gccatctgtt gtttgccct ccccccgtgcc ttcccttgacc ctggaaagggt 1920
 ccactccac tgcctttcc taataaaaatg agggaaattgc atcgcattgt ctgagtaggt 1980
 gt
 1982

50 <210> 10
 <211> 1982
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <221> CDS
 <222> (207)..(1823)
 <223> Polynucleotide and polypeptide sequence coding bispecific antibody

	<400>	10		
5	aatgggagtt tggggca cccaaatcaa cgggacttcc caaatgtcg taacaactcc gccccattga cgccaaatggg cggtaggcgt gtacgggggg aggtctatat aagcagagct ctctggctaa ctagagaacc cactgcttc tggttatcg aaattaatac gactcaat agggagaccc aagctggcta gccacc atg gag aca gac aca ctc ctg cta tgg Met Glu Thr Asp Thr Leu Leu Leu Trp	60 120 180 233		
	1 5			
10	gta ctg ctg ctc tgg gtt cca ggt tcc act ggt gac gcg gcc cag ccg Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly Asp Ala Ala Gln Pro 10 15 20 25	281		
	gcc agg cgc gcc gta cga agc tta cag gtc cag ctg cag gag tca gga Ala Arg Arg Ala Val Arg Ser Leu Gln Val Gln Leu Gln Glu Ser Gly 30 35 40	329		
15	cct ggc ctg gtg aaa cct tct cag tct ctg tcc ctc acc tgc act gtc Pro Gly Leu Val Lys Pro Ser Gln Ser Leu Ser Leu Thr Cys Thr Val 45 50 55	377		
	act ggc cac tca atc acc agt gat tat gcc tgg aac tgg atc cgg cag Thr Gly His Ser Ile Thr Ser Asp Tyr Ala Trp Asn Trp Ile Arg Gln 60 65 70	425		
20	ttt cca gga gac aaa ctg gag tgg atg ggc tac ata agc tac agt ggt Phe Pro Gly Asp Lys Leu Glu Trp Met Gly Tyr Ile Ser Tyr Ser Gly 75 80 85	473		
	tac act acc tac aac cca tct ctg aaa agt cga gtc tct atc act cga Tyr Thr Thr Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Thr Arg 90 95 100 105	521		
25	gac aca tcc aag aac cag ttc ttc ctg cag ttg aat tct gtg act act Asp Thr Ser Lys Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Thr 110 115 120	569		
	gag gac aca gcc aca tac ttc tgt gca aga gac ctt gat tac ggc ccc Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Leu Asp Tyr Gly Pro 125 130 135	617		
30	tgg ttt gct tac tgg ggc caa ggg acc acg gtc acc gtc tcc tca ggt Trp Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Ser Ser Gly 140 145 150	665		
	gga ggc ggt tca caa att gtt ctc acc cag tct cca gca atc atg tct Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser 155 160 165	713		
35	gca tct cca ggg gag aag gtc acc atg acc tgc agt gcc agc tca agt Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser 170 175 180 185	761		
	gta agt tac atg aac tgg tac cag cag aag tca ggc acc tcc ccc aaa Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys 190 195 200	809		
40	aga tgg att tat gac aca tcc aaa ctg gct tct gga gtc cct gct cac Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala His 205 210 215	857		
	tcc agg ggc agt ggg tct ggg acc tct tac tct ctc aca atc agc ggc Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Gly 220 225 230	905		
45	atg gag gct gaa gat gct gcc act tat tac tgc cag cag tgg agt agt Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser 235 240 245	953		
	aac cca ttc acg ttc ggc tcg ggg aca aag ttg gaa ata aac cgg ggt Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn Arg Gly 250 255 260 265	1001		
50	gga ggc ggt tca ggc gga ggt ggc tct ggc ggt ggc gga tcg cag gtc Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Gly Ser Gln Val 270 275 280	1049		
	cag ctg cag cag tct ggg gct gaa ctg gca aga cct ggg gcc tca gtg Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val 285 290 295	1097		
55	aag atg tcc tgc aag gct tct ggc tac acc ttt act agg tac acg atg Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met 300 305 310	1145		
	cac tgg gta aaa cag agg cct gga cag ggt ctg gaa tgg att gga tac His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr 315 320 325	1193		

	att aat cct agc cgt ggt tat act aat tac aat cag aag ttc aag gac Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp 330 335 340 345	1241
5	aag gcc aca ttg act aca gac aaa tcc tcc agc aca gcc tac atg caa Lys Ala Thr Leu Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln 350 355 360 365	1289
	ctg agc agc ctg aca tct gag gac tct gca gtc tat tac tgt gca aga Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg 365 370 375	1337
10	tat tat gat gat cat tac tgc ctt gac tac tgg ggc caa ggc acc act Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr 380 385 390	1385
	ctc aca gtc tcc tca ggt gga ggc ggt tca gac atc cag atg acc cag Leu Thr Val Ser Ser Gly Gly Gly Ser Asp Ile Gln Met Thr Gln 395 400 405	1433
15	tct cca gcc tcc cta tct gca tct gtg gga gaa act gtc acc ctc aca Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Leu Thr 410 415 420 425	1481
	tgt cga gca agt gag aat att cac aat tat tta gca tgg tat cag cag Cys Arg Ala Ser Glu Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln 430 435 440	1529
20	aaa cag gga aaa tct cct cag ctc ctg gtc tat aat gta aaa acc tta Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Val Lys Thr Leu 445 450 455	1577
	gca gat ggt gtg cca tca agg ttc agt ggc agt gga tca gga aca caa Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln 460 465 470	1625
25	tat tct ctc aag atc aac agc ctg cag cct gaa gat ttt ggg agt tat Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr 475 480 485	1673
	tac tgt caa cat ttt tgg agt agt ccg tgg acg ttc ggt gga ggc acc Tyr Cys Gln His Phe Trp Ser Ser Pro Trp Thr Phe Gly Gly Thr 490 495 500 505	1721
30	aag ctg gaa atc aaa cgg gcg gcc gct cga gga ggg ccc gaa caa aaa Lys Leu Glu Ile Lys Arg Ala Ala Ala Arg Gly Gly Pro Glu Gln Lys 510 515 520	1769
	ctc atc tca gaa gag gat ctg aat agc gcc gtc gac cat cat cat cat Leu Ile Ser Glu Glu Asp Leu Asn Ser Ala Val Asp His His His His 525 530 535	1817
35	cat cat tgagttaaa cccgctgatc agcctcgact gtgccttcta gttgccagcc His His atctgttgtt tgccccctccc ccgtgccttc cttgacccttg gaagggtgcca ctccccactgt cctttctcaa taaaatgagg aaattgcatc gcattgtctg agtaggtgt	1873 1933 1982
	<210> 11 <211> 539 <212> PRT 40 <213> Artificial Sequence <223> Polypeptide sequence coding bispecific antibody	
	<400> 11 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ala Ala Gln Pro Ala Arg Arg Ala Val Arg Ser 20 25 30 Leu Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser 35 40 45 Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly His Ser Ile Thr Ser 50 55 60 Asp Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asp Lys Leu Glu 65 70 75 80 Trp Met Gly Tyr Ile Ser Tyr Ser Gly Tyr Thr Thr Tyr Asn Pro Ser 85 90 95 Leu Lys Ser Arg Val Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe 100 105 110 Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Phe 115 120 125 Cys Ala Arg Asp Leu Asp Tyr Gly Pro Trp Phe Ala Tyr Trp Gly Gln	

	130	135	140
	Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly	Gly Ser Gln Ile Val	
5	145 150	155	160
	Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro	Gly Glu Lys Val	
	165	170	175
	Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr	Met Asn Trp Tyr	
	180	185	190
	Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile	Tyr Asp Thr Ser	
	195	200	205
10	Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg	Gly Ser Gly Ser Gly	
	210	215	220
	Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala	Glu Asp Ala Ala	
	225	230	235
	Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro	Phe Thr Phe Gly Ser	
	245	250	255
15	Gly Thr Lys Leu Glu Ile Asn Arg Gly Gly Gly Ser	Gly Gly Gly Gly	
	260	265	270
	Gly Ser Gly Gly Gly Ser Gln Val Gln Leu Gln Gln	Ser Gly Ala	
	275	280	285
	Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser	Cys Lys Ala Ser	
	290	295	300
20	Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val	Lys Gln Arg Pro	
	305	310	315
	Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro	Ser Arg Gly Tyr	
	325	330	335
	Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala	Thr Leu Thr Thr Asp	
	340	345	350
	Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser	Leu Thr Ser Glu	
	355	360	365
25	Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp	Asp Asp His Tyr Cys	
	370	375	380
	Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val	Ser Ser Gly Gly	
	385	390	395
	Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ala	Ser Leu Ser Ala	
	405	410	415
30	Ser Val Gly Glu Thr Val Thr Leu Thr Cys Arg Ala	Ser Glu Asn Ile	
	420	425	430
	His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln	Gly Lys Ser Pro Gln	
	435	440	445
	Leu Leu Val Tyr Asn Val Lys Thr Leu Ala Asp	Gly Val Pro Ser Arg	
	450	455	460
35	Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu	Lys Ile Asn Ser	
	465	470	475
	Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys	Gln His Phe Trp Ser	
	485	490	495
	Ser Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile	Lys Arg Ala	
	500	505	510
40	Ala Ala Arg Gly Gly Pro Glu Gln Lys Leu Ile Ser	Glu Glu Asp Leu	
	515	520	525
	Asn Ser Ala Val Asp His His His His His		
	530	535	
45	<210> 12		
	<211> 1617		
	<212> DNA		
	<213> Artificial Sequence		
	<223> Polynucleotide sequence coding bispecific antibody		
	<400> 12		
50	atggagacag acacactcct gctatggta ctgctgctct gggttccagg ttccactgg	60	
	gacgcggccc agccggccag gcgcgcgtt cgaacctac aggtccagct gcaggagtca	120	
	ggacacctggcc tggtgaaacc ttctcagttt ctgtccctca cctgcactgt cactggccac	180	
	tcaatcacca gtgattatgc ctggactgg atccggcagt ttccaggaga caaactggag	240	
	tggatgggct acataagcta cagtggttac actacctaca acccatctt gaaaagtctga	300	
55	gtctctatca ctcgagacac atccaagaac cagttttcc tgcagttgaa ttctgtgact	360	
	actgaggaca cagccacata cttctgtcga agagacccatg attacggccc ctgggttgct	420	
	tactggggcc aagggaccac ggtcaccgtc tcctcagggtg gagggcggttc acaaattgtt	480	
	ctcacccagt ctccagcaat catgtctgca tctccagggg agaagggtcac catgacccgtc	540	

	agtgccagct	caagtgttaag	ttacatgaac	tggtaccgc	agaagtcaagg	cacccccc	600
	aaaagatgga	tttatgacac	atccaaactg	gcttctggag	tccctgctca	cttcaggggc	660
	agtgggtctg	ggaccttta	ctctctcaca	atcagcggca	tggaggctga	agatgtgcc	720
	acttattact	gccagcagt	gagtagtaac	ccattcacgt	tcggctcggy	gacaagaattg	780
5	gaaataaacc	ggggtgagg	cggttccgc	ggaggtggct	ctggcggtgg	cgatccgcag	840
	gtccagctgc	agcagtctgg	ggctgaact	gcaagacact	gggcctcagt	gaagatgtcc	900
	tgcaaggctt	ctggctacac	ctttaactagg	tacacgtgc	actgggtaaa	acagaggcct	960
	ggacagggtc	tggaaatggat	tggatacatt	aatccctagcc	gtggttatac	taattacaat	1020
	cagaagttca	aggacaaggc	cacattgact	acagacaaat	cctccagcac	agcctacatg	1080
	caactgagca	gcctgacatc	tgaggactct	gcagtctatt	actgtcaag	atattatgat	1140
10	gatcattact	gccttgacta	ctggggccaa	ggcaccactc	tcacagtctc	ctcagggtgg	1200
	ggcggttcag	acatccagat	gaccctgtct	ccagcctccc	tatctgcac	tgtgggagaa	1260
	actgtcaccc	tcacatgtcg	agcaagtgag	aatattcaca	attatttgc	atggatcatcg	1320
	cagaaacagg	gaaatctcc	tcagctctg	gtctataatg	taaaaaatgg	agcagatgg	1380
	gtgcccatt	ggttcagtgg	cagtggatca	ggaaacaaat	attctctcaa	gatcaacagc	1440
	ctgcaggctg	aagattttgg	gaggattttac	tgtcaacatt	tttggagtag	tccgtggacg	1500
15	ttcgggtggag	gcacccaatct	ggaaatcaaa	cgggcggccg	ctcgaggagg	gccccaaacaa	1560
	aaactcatct	cagaagagga	tctgaatgc	gccgtcgacc	atcatcatca	tcatcat	1617
	<210>	13					
	<211>	1434					
	<212>	DNA					
20	<213>	Artificial Sequence					
	<223>	Polynucleotide sequence coding bispecific antibody					
	<400>	13					
	caggtccagc	tgcaggagtc	aggacctggc	ctggtgaaac	cttctcagtc	tctgtccctc	60
	acctgcactg	tcactggcca	ctcaatcacc	agtgattatg	cctggaaactg	gatccggcag	120
25	tttccaggag	acaaaactgg	gtggatggc	tacataagct	acatgggttc	cactacctac	180
	aaccctatctc	tgaaaaggatcg	agtctctatc	actcgagaca	catccaaagaa	ccagttcttc	240
	ctgcaggatgc	atttctgtac	tactggagac	acagccacat	acttctgtgc	aagagacatt	300
	gattacggcc	cctgggtttgc	ttactggggc	caagggacca	cggtcacccgt	ctcctcagg	360
	ggaggcggtt	cacaaattgt	tctcaccagg	tctccagaa	tcatgtctgc	atctccagg	420
	gagaaggatca	ccatgacatcg	cagtgcacgc	tcaagtgtaa	gttacatgaa	ctggtaccag	480
30	cagaagtcag	gcacccccc	aaaaagatgg	attttatgaca	catccaaact	ggcttctgg	540
	gtccctgtctc	acttcagggg	cagtgggtct	gggacctctt	acttctctac	aatcagcggc	600
	atggaggctg	aagatgtcg	cacttattac	tgcggcaggt	ggagtagtaa	cccattcacg	660
	ttcggctcg	ggacaaaatgtt	ggaaaataaac	cgggggtggag	gcgggttcagg	cgagggtggc	720
	tctggcgggt	gcggatcgca	ggtccagctg	cagcgtctg	gggctgtaaact	ggcaagacct	780
	ggggccctcg	tgaagatgtc	ctgcaaggct	tctggctaca	cttttactag	gtacacgt	840
35	caactggtaa	aacagaggcc	tggacagggt	ctggaaatgg	ttggatacat	taatccatgc	900
	cgtggttata	ctaattacaa	tcagaaggtc	aaggacaagg	ccacattgac	tacagacaaa	960
	tcctccagca	cagcctacat	gcaactgagc	agcctgacat	ctgaggactc	tgcagtctat	1020
	tactgtgcaa	gatattatga	tgatcattac	tgccttgcact	actggggcc	aggcaccact	1080
	ctcacagtc	cctcagggtgg	aggcggttca	gacatccaga	tgacccagtc	tccagcctcc	1140
	ctatgtcat	ctgtgggaga	aactgtcacc	ctcacatgtc	gagcaagtg	aatatttcac	1200
40	aattatttag	catggatata	gcagaaaacag	ggaaaatctc	ctcagctct	gttctataat	1260
	gtaaaaaacct	tagcagatgg	tgtgcccatt	aggttcagt	gcagtggatc	aggaacacaa	1320
	tattctctca	agatcaacag	cctgcagct	gaagattttg	ggagtttata	ctgtcaacat	1380
	ttttggatgt	gtccgtggac	gttcgggtgg	ggcaccaagc	tggaaatcaa	acgg	1434
	<210>	14					
	<211>	34					
45	<212>	DNA					
	<213>	Artificial Sequence					
	<223>	PCR primer oligonucleotide					
	<400>	14					
	tttttaaagc	ttacaggatcc	agctgcagga	gtca			34
50	<210>	15					
	<211>	34					
	<212>	DNA					
	<213>	Artificial Sequence					
	<223>	PCR primer oligonucleotide					
55	<400>	15					
	ttttttgcgg	ccgccccgggtt	tatttccaaac	tttg			34

5 <210> 16
<211> 34
<212> DNA
<213> Artificial Sequence
<223> PCR primer oligonucleotide

10 <400> 16
ttttttaagc ttacagggtcc agctgcagca gtct

15 <210> 17
<211> 34
<212> DNA
<213> Artificial Sequence
<223> PCR primer oligonucleotide

20 <400> 17
tttttgccgg ccgccccgttt gatttccagc ttgg

25 <210> 18
<211> 21
<212> DNA
<213> Artificial Sequence
<223> PCR primer oligonucleotide

30 <400> 18
atgaacttgtt accagcagaa g
21

35 <210> 19
<211> 65
<212> DNA
<213> Artificial Sequence
<223> Linker oligonucleotide

40 <400> 19
agggaccacg gtcaccgtct cctcaggtgg aggcggttca caaattgttc tcacccagtc
tccag
65

45 <210> 20
<211> 65
<212> DNA
<213> Artificial Sequence
<223> Linker oligonucleotide

50 <400> 20
ctggagactg ggtgagaaca atttgtgaac cgcccccacc tgaggagacg gtgaccgtgg
tccct
65

55 <210> 21
<211> 65
<212> DNA
<213> Artificial Sequence
<223> Linker oligonucleotide

60 <400> 21
aggcaccact ctcacagtct cctcaggtgg aggcggttca gacatccaga tgacccagtc
tccag
65

65 <210> 22
<211> 65
<212> DNA
<213> Artificial Sequence
<223> Linker oligonucleotide

	<400> 22			
	ctggagactg ggtcatctgg atgtctgaac cgcctccacc tgaggagact gtgagagtgg			60
	tgcct			65
5	<210> 23			
	<211> 95			
	<212> DNA			
	<213> Artificial Sequence			
	<223> Linker oligonucleotide			
10	<400> 23			
	ggggacaaaag ttggaaataa accggggtgg aggcggttca ggccggaggtg gctctggcgg			60
	tggcgatcg caggccagc tgcagcagtc tgggg			95
	<210> 24			
	<211> 95			
15	<212> DNA			
	<213> Artificial Sequence			
	<223> Linker oligonucleotide			
	<400> 24			
20	ccccagactg ctgcagctgg acctgcgatc cgccaccgcc agagccacct ccgcctgaac			60
	cgcctccacc ccggtttatt tccaactttg tcccc			95
	<210> 25			
	<211> 5			
	<212> PRT			
	<213> Artificial Sequence			
25	<223> Linker polypeptide			
	<400> 25			
	Gly Gly Gly Gly Ser			
	1 5			
30	<210> 26			
	<211> 15			
	<212> PRT			
	<213> Artificial Sequence			
	<223> Linker polypeptide			
35	<400> 26			
	Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser			
	1 5 10 15			

40 **Claims**

1. A substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells, and a linker.
- 45 2. The substance specific to human PD-1 according to claim 1, wherein the part that recognizes human PD-1 is an antibody against human PD-1 or a partial fragment thereof.
3. The substance specific to human PD-1 according to claim 1, wherein the part that recognizes a membrane protein on cell membrane of human PD-1-expressing cells is an antibody against the membrane protein or a partial fragment thereof.
- 50 4. The substance specific to human PD-1 according to claim 1, comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against the membrane protein on cell membrane of human PD-1-expressing cells or a partial fragment thereof, and a linker.
- 55 5. The substance specific to human PD-1 according to any one of claims 1, 3 and 4, wherein the membrane protein is human T cell receptor complex or human B cell receptor complex.

6. The substance specific to human PD-1 according to claim 1 or 4, wherein the linker is a peptide.
7. A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human T cell receptor complex or a partial fragment thereof, and a linker.
8. A bispecific antibody comprising an antibody against human PD-1 or a partial fragment thereof, an antibody against human B cell receptor complex or a partial fragment thereof, and a linker.
9. The bispecific antibody according to claim 7 or 8, wherein the linker is a peptide.
10. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
11. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:4, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, wherein the polypeptide composes an antibody against human PD-1.
12. A polypeptide complex comprising the polypeptides according to claims 10 and 11.
13. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added.
14. A substantially pure polypeptide comprising the amino acid sequence represented by SEQ ID NO:11, a homolog thereof, a fragment thereof or a homolog of the fragment, or a polypeptide comprising the amino acid sequence to which 1-10 amino acid(s) of the polypeptide is/are deleted, substituted, and/or added, which is the bispecific antibody according to any one of claims 7 to 9.
15. A polynucleotide encoding the polypeptide according to any one of claims 10, 11, 13 and 14, a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
16. A polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:9, a homolog thereof or a complementary polynucleotide thereof, or a fragment thereof or a homolog of the fragment.
17. A duplication or expression vector comprising the polynucleotide according to claim 15 or 16.
18. A host cell transformed by the duplication or expression vector according to claim 17.
19. A manufacturing method of the substance according to any one of claims 1 to 6, comprising culturing the host cell according to claim 18 under conditions to express the substance.
20. A manufacturing method of the bispecific antibody according to any one of claims 7 to 9, comprising culturing the host cell according to claim 18 under conditions to express the bispecific antibody.
21. A manufacturing method of the polypeptide according to any one of claims 10 to 14, comprising culturing the host cell according to claim 18 under conditions to express the polypeptide.
22. A therapeutic and/or preventive pharmaceutical composition for human PD-1 related-diseases, comprising an effective amount of the substance according to any one of claims 1 to 6, the bispecific antibody according to any one of claims 7 to 9, the polypeptide complex according to claim 12, or the polypeptide according to claim 13 or 14.
23. The therapeutic and/or preventive pharmaceutical composition according to claim 22, wherein the human PD-1 related-diseases are diseases selected from neurodegenerative disease, autoimmune disease, collagenosis, organ transplantation rejection, tumour, and infectious disease.

24: The therapeutic and/or preventive pharmaceutical composition according to claim 22, wherein the neurodegenerative diseases are diseases selected from geropsychosis, Alzheimer disease, Down syndrome, Parkinson's disease, Creutzfeldt-jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt-Jakob disease.

5

25. The therapeutic and/or preventive pharmaceutical composition according to claim 22, wherein the autoimmune diseases are diseases selected from glomerular nephritis, arthritis, dilated cardiomyopathy-like disease, ulcerous colitis, Sjogren syndrome, Crohn disease, systemic erythematoses, chronic rheumatoid arthritis, multiple sclerosis, psoriasis, allergic contact dermatitis, polymyositis, pachyderma, periarteritis nodosa, rheumatic fever, vitiligo vulgaris, insulin dependent diabetes mellitus, Behcet disease, Hashimoto disease, Addison disease, dermatomyositis, myasthenia gravis, Reiter syndrome, Graves' disease, anaemia perniciosa, Goodpasture syndrome, sterility disease, chronic active hepatitis, pemphigus, autoimmune thrombopenic purpura, and autoimmune hemolytic anemia.

10

15

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2





FIG. 3



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/000549

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl' C12N15/13, C07K16/46, C12P21/08, C12N5/10, A61K39/395		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl' C12N15/00-15/90, C07K14/00-16/46, C12P1/00-41/00, C12N1/00-9/99, A61K31/00-48/00		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) SwissProt/PIR/GeneSeq, GenBank/EMBL/DDBJ/GeneSeq, WPI (STN), BIOSIS (STN), MEDLINE (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Wayne W. Hancock3 et al., "Programmed Death-1 Targeting Can Promote Allograft Survival.", The Journal of Immunology, Vol.169, (2002), pages 6546 to 6553	1-25
Y	Honjo T. et al., "PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.", Eur.J.Immunol., Vol.32, No.3, (2002), pages 634 to 643	1-25
Y	Margitta Alt et al., "Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin 1 Fc or CH3 region.", FEBS Letters, Vol.454, Issues 1-2, (1999), pages 90 to 94	1-25
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 02 June, 2004 (02.06.04)	Date of mailing of the international search report 22 June, 2004 (22.06.04)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Facsimile No.	Telephone No.	

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/000549

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Peter J. et al., "High avidity scFv multimers; diabodies and triabodies.", Journal of Immunological Methods, Vol.231, (1999), pages 177 to 189	1-25
Y	WO 2001/064249 A1 (Chugai Pharmaceutical Co., Ltd.), 07 September, 2001 (07.09.01), & JP 2001-563146 A	1-25

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/000549

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - a sequence listing
 - table(s) related to the sequence listing
 - b. format of material
 - in written format
 - in computer readable form
 - c. time of filing/furnishing
 - contained in the international application as filed
 - filed together with the international application in computer readable form
 - furnished subsequently to this Authority for the purposes of search
2. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments: